ES2828504T3 - Compuestos farmacéuticos - Google Patents

Compuestos farmacéuticos Download PDF

Info

Publication number
ES2828504T3
ES2828504T3 ES17790813T ES17790813T ES2828504T3 ES 2828504 T3 ES2828504 T3 ES 2828504T3 ES 17790813 T ES17790813 T ES 17790813T ES 17790813 T ES17790813 T ES 17790813T ES 2828504 T3 ES2828504 T3 ES 2828504T3
Authority
ES
Spain
Prior art keywords
benzo
pyrrolidin
dimethylisoxazol
imidazol
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17790813T
Other languages
English (en)
Spanish (es)
Inventor
Neil Anthony Pegg
Stuart Thomas Onions
David Michel Adrien Taddei
Jonathan Shannon
Silvia Paoletta
Richard James Brown
Don Smyth
Gareth Harbottle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CellCentric Ltd
Original Assignee
CellCentric Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CellCentric Ltd filed Critical CellCentric Ltd
Application granted granted Critical
Publication of ES2828504T3 publication Critical patent/ES2828504T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES17790813T 2016-10-18 2017-10-18 Compuestos farmacéuticos Active ES2828504T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1617630.7A GB201617630D0 (en) 2016-10-18 2016-10-18 Pharmaceutical compounds
PCT/GB2017/053152 WO2018073586A1 (en) 2016-10-18 2017-10-18 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
ES2828504T3 true ES2828504T3 (es) 2021-05-26

Family

ID=57680668

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17790813T Active ES2828504T3 (es) 2016-10-18 2017-10-18 Compuestos farmacéuticos

Country Status (23)

Country Link
US (2) US10696666B2 (enExample)
EP (1) EP3529248B1 (enExample)
JP (1) JP7152393B2 (enExample)
KR (1) KR102578786B1 (enExample)
CN (1) CN110049983B (enExample)
AU (1) AU2017346453B2 (enExample)
CY (1) CY1123666T1 (enExample)
DK (1) DK3529248T3 (enExample)
EA (1) EA201990643A1 (enExample)
ES (1) ES2828504T3 (enExample)
GB (1) GB201617630D0 (enExample)
HR (1) HRP20201444T1 (enExample)
HU (1) HUE052443T2 (enExample)
IL (1) IL266017B (enExample)
LT (1) LT3529248T (enExample)
MX (1) MX384438B (enExample)
PT (1) PT3529248T (enExample)
RS (1) RS61007B1 (enExample)
SG (1) SG11201903155XA (enExample)
SI (1) SI3529248T1 (enExample)
SM (1) SMT202000593T1 (enExample)
WO (1) WO2018073586A1 (enExample)
ZA (1) ZA201902334B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201617630D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
GB201617627D0 (en) * 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
WO2019055877A1 (en) 2017-09-15 2019-03-21 Forma Therapeutics, Inc. TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300
GB201806320D0 (en) * 2018-04-18 2018-05-30 Cellcentric Ltd Process
KR20250067962A (ko) 2018-06-29 2025-05-15 포르마 세라퓨틱스 인크. Creb 결합 단백질(cbp)의 저해
US12351577B2 (en) 2019-03-15 2025-07-08 Forma Therapeutics, Inc. Inhibiting cyclic AMP-responsive element-binding protein (CREB)
EP3937936A4 (en) * 2019-03-15 2022-12-28 Forma Therapeutics, Inc. INHIBITION OF CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB)
CN112574178B (zh) * 2019-09-27 2025-12-16 海创药业股份有限公司 一种氘代苯并咪唑类化合物及其作为ep300/cbp抑制剂的用途
CN112574189B (zh) * 2019-09-27 2024-05-31 海创药业股份有限公司 一种ep300/cbp抑制剂
CN112574191B (zh) * 2019-09-29 2024-01-23 南京圣和药业股份有限公司 异噁唑杂环类化合物及其应用
AU2021298154A1 (en) 2020-06-25 2023-02-23 Tolremo Therapeutics Ag Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer
BR112022025911A2 (pt) 2020-06-25 2023-01-10 Tolremo Therapeutics Ag Combinação de um inibidor de bromodomínio de cbp/p300 e um inibidor de egfr para uso no tratamento de um cpcnp com egfr mutante
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
TW202227429A (zh) * 2020-11-06 2022-07-16 大陸商貝達藥業股份有限公司 P300抑制劑、包含其的藥物組合物、其應用及製備其的方法
JPWO2022138944A1 (enExample) * 2020-12-25 2022-06-30
CN116670129A (zh) * 2020-12-31 2023-08-29 南京明德新药研发有限公司 苯并咪唑类化合物及其应用
CN114989158A (zh) * 2021-03-02 2022-09-02 复旦大学 组蛋白乙酰转移酶p300溴结构域抑制剂及其药用组合物及其应用
WO2022184664A1 (en) 2021-03-02 2022-09-09 Boehringer Ingelheim International Gmbh Anticancer combination therapy
EP4257130A1 (de) * 2022-04-08 2023-10-11 Justus-Liebig-Universität Gießen Inobrodib zur behandlung von pulmonaler arterieller hypertonie
CN117645603A (zh) * 2022-09-05 2024-03-05 复旦大学 p300溴结构域抑制剂及其药用组合物及其应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE27997A1 (es) 1994-04-29 1997-09-20 Lilly Co Eli Antagonistas de receptores de taquicininas
AU5636900A (en) * 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
CA2425185A1 (en) 2000-10-06 2002-04-11 Stephane De Lombaert Benzimidazole and indole derivatives as crf receptor modulators
EP1377549A1 (en) 2001-03-12 2004-01-07 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
EP1490058B1 (en) 2002-02-21 2007-10-10 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
WO2004063151A2 (en) 2003-01-03 2004-07-29 Bristol-Myers Squibb Company Novel tyrosine kinase inhibitors
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
JP2008501714A (ja) 2004-06-04 2008-01-24 武田薬品工業株式会社 ジペプチジルペプチダーゼインヒビター
WO2006124780A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase
WO2006136823A1 (en) 2005-06-21 2006-12-28 Astex Therapeutics Limited Heterocyclic containing amines as kinase b inhibitors
JP5536336B2 (ja) * 2005-11-08 2014-07-02 チョンウェ ファーマ コーポレイション α−ヘリックス類似体および癌幹細胞の治療に関する方法
EP1878724A1 (en) 2006-07-15 2008-01-16 sanofi-aventis A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles
EP2091329A4 (en) 2006-12-05 2011-02-23 Univ Nat Chiao Tung Indazole CONNECTIONS
AU2008267444A1 (en) 2007-06-26 2008-12-31 Sanofi-Aventis A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles
US20120121540A1 (en) 2007-08-10 2012-05-17 Franz Ulrich Schmitz Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections
US20110052562A1 (en) 2007-12-19 2011-03-03 The Scripps Research Institute Benzimidazoles and analogs as rho kinase inhibitors
US8501957B2 (en) 2008-12-10 2013-08-06 China Medical University Benzimidazole compounds and their use as anticancer agents
WO2010068287A2 (en) 2008-12-11 2010-06-17 Angion Biomedica Corp. Small molecule modulators of hepatocyte growth factor (scatter factor) activity
US20120040916A1 (en) 2008-12-22 2012-02-16 Massachusetts Institute Of Technology Molecular inhibitors of the wnt/beta-catenin pathway
EP2501696B1 (en) 2009-10-15 2016-12-28 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
US9005670B2 (en) * 2010-01-05 2015-04-14 The Johns Hopkins University Use of histone acetyltransferase inhibitors as novel anti-cancer therapies
US8455516B2 (en) 2010-01-15 2013-06-04 Touro University HIV-1 fusion inhibitors and methods
WO2011097607A1 (en) 2010-02-08 2011-08-11 Southern Research Institute Anti-viral treatment and assay to screen for anti-viral agent
MX2012013128A (es) 2010-05-13 2013-03-20 Amgen Inc Compuestos heterociclicos de nitrogeno como inhibidores de la fosfodiesterasa 10.
EP2397471A1 (en) 2010-06-16 2011-12-21 China Medical University Benzimidazole compounds and their use
JP5850503B2 (ja) 2010-09-14 2016-02-03 北海道公立大学法人 札幌医科大学 筋ジストロフィーを処置するための組成物
RU2013138835A (ru) 2011-02-09 2015-03-20 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения в качестве ингибиторов pi3 киназы
EP2681200A4 (en) 2011-03-03 2015-05-27 Zalicus Pharmaceuticals Ltd INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL
JP2014114212A (ja) 2011-03-29 2014-06-26 Dainippon Sumitomo Pharma Co Ltd 新規ベンズイミダゾール誘導体
TW201348231A (zh) 2012-02-29 2013-12-01 Amgen Inc 雜雙環化合物
CA2874303C (en) 2012-06-11 2020-10-13 Ucb Biopharma Sprl Tnf -alpha modulating benz imidazoles
WO2014012050A2 (en) 2012-07-13 2014-01-16 Indiana University Research & Technology Corporation Compounds for treatment of spinal muscular atrophy
JP2016000697A (ja) 2012-10-02 2016-01-07 大日本住友製薬株式会社 ピリミジン誘導体
JP2014073982A (ja) 2012-10-03 2014-04-24 Dainippon Sumitomo Pharma Co Ltd 新規ベンズイミダゾール誘導体からなる医薬
EP2919770A4 (en) 2012-11-14 2017-03-08 The Board of Regents of The University of Texas System Inhibition of hif-2 heterodimerization with hif1 (arnt)
WO2014157382A1 (ja) 2013-03-29 2014-10-02 味の素株式会社 スフィンゴシンキナーゼ阻害剤
PL231063B1 (pl) 2013-04-10 2019-01-31 Oncoarendi Therapeutics Spolka Z Ograniczona Odpowiedzialnoscia Pochodne 1-(podstawionej sulfonylo)-2-aminoimidazoliny jako środki przeciwnowotworowe
TWI527811B (zh) * 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
WO2015004533A2 (en) * 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
US10471139B2 (en) 2013-08-15 2019-11-12 The University Of Kansas Toll-like receptor agonists
GB201321741D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
KR102494596B1 (ko) 2014-07-31 2023-01-31 재단법인 한국파스퇴르연구소 2-아미노-벤즈이미다졸 유도체 및 5-리폭시게나아제 및/또는 프로스타글란딘 e 합성효소 억제제로서의 이들의 용도
WO2016086200A1 (en) 2014-11-27 2016-06-02 Genentech, Inc. 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
GB201506658D0 (en) * 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506660D0 (en) * 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
WO2016200401A1 (en) 2015-06-12 2016-12-15 Transitions Optical, Inc. Alignment compounds
CA2994478C (en) 2015-08-12 2023-10-03 Neomed Institute Substituted benzimidazoles, their preparation and their use as pharmaceuticals
WO2017059252A1 (en) 2015-10-02 2017-04-06 Gilead Sciences, Inc. Combinations of the btk inhibitor gs-4059 with inhibitors selected from a jak, ask1, brd and/or mmp9 inhibitor to treat cancer, allergic disorders, autoimmune diseases or inflammatory diseases
WO2017100525A1 (en) 2015-12-11 2017-06-15 The Board Of Regents Of The University Of Texas System Substituted benzimidazolium, pyrido-imidazolium, or pyrazino-imidazolium compounds as chemotherapeutics
WO2017106568A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a bromodomain inhibitor for treating cancer
CA3027500A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
WO2017223229A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
GB201617630D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
GB201617627D0 (en) * 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
WO2018097976A1 (en) 2016-11-22 2018-05-31 Gilead Sciences, Inc. Synthesis of a compound that modulates the activity of bromodomain-containing proteins

Also Published As

Publication number Publication date
CA3039641A1 (en) 2018-04-26
KR102578786B1 (ko) 2023-09-15
US20200407349A1 (en) 2020-12-31
US20190375740A1 (en) 2019-12-12
CY1123666T1 (el) 2022-03-24
HUE052443T2 (hu) 2021-04-28
KR20190075095A (ko) 2019-06-28
US11377443B2 (en) 2022-07-05
GB201617630D0 (en) 2016-11-30
US10696666B2 (en) 2020-06-30
EP3529248A1 (en) 2019-08-28
CN110049983B (zh) 2022-06-14
BR112019007834A2 (pt) 2019-07-16
HRP20201444T1 (hr) 2020-12-11
MX2019004113A (es) 2019-09-09
MX384438B (es) 2025-03-14
SMT202000593T1 (it) 2020-11-10
JP7152393B2 (ja) 2022-10-12
SG11201903155XA (en) 2019-05-30
RS61007B1 (sr) 2020-11-30
EP3529248B1 (en) 2020-08-19
PT3529248T (pt) 2020-09-03
AU2017346453B2 (en) 2022-02-17
EA201990643A1 (ru) 2019-11-29
ZA201902334B (en) 2022-10-26
CN110049983A (zh) 2019-07-23
WO2018073586A1 (en) 2018-04-26
IL266017B (en) 2021-08-31
SI3529248T1 (sl) 2020-11-30
DK3529248T3 (da) 2020-09-14
JP2019537571A (ja) 2019-12-26
IL266017A (en) 2019-06-30
NZ752354A (en) 2025-02-28
LT3529248T (lt) 2020-10-26
AU2017346453A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
KR102578786B1 (ko) 약학적 화합물
JP7755632B2 (ja) 統合的ストレス経路のモジュレーター
JP7617890B2 (ja) タンパク質チロシンホスファターゼ阻害物質及びその使用方法
CN115867554B (zh) Brm靶向化合物和相关使用方法
JP7089061B2 (ja) サイクリン依存性キナーゼ阻害剤としての2-アミノ-ピリジンまたは2-アミノ-ピリミジン誘導体
US8962623B2 (en) Aminopyrazine compounds
ES2824814T3 (es) Compuestos farmacéuticos
JP7003114B2 (ja) 統合ストレス経路のモジュレーター
DK2684880T3 (en) DISPIROPYRROLIDINE DERIVATIVES
ES2968007T3 (es) Inhibidores heterocíclicos de ERK1 y ERK2 y su uso en el tratamiento de cáncer
EP2807153B1 (en) Heterocyclic compounds and methods for their use
KR20240020735A (ko) Cdk2 분해제 및 그 용도
TW201219383A (en) Chemical compounds
AU2015239098A1 (en) Macrocylic pyrimidine derivatives
CN107849036A (zh) 二环化合物
CA3200164A1 (en) Salt and crystal form of nitrogen-containing heterocyclic derivative, preparation method therefor and application thereof
CA3039641C (en) Arylimidazolyl isoxazole compounds and their use as modulators of p300 and/or cbp
BR112019007834B1 (pt) Compostos farmacêuticos
EA041318B1 (ru) Арилимидазолилизоксазолы и их применение
EA052032B1 (ru) Новые соединения в качестве двойных ингибиторов андрогенового рецептора и фосфодиэстеразы
HK40006202B (en) Pharmaceutical compounds
HK40006202A (en) Pharmaceutical compounds
EA044376B1 (ru) Соединения замещенного 3-((3-аминофенил)амино)пиперидин-2,6-диона, их композиции и способы лечения с их помощью